Scotland Approves Procysbi for Cystinosis Treatment
The Scottish Medicines Consortium made a key decision on November 10, 2025, to approve mercaptamine, sold as Procysbi, for treating cystinosis in Scotland. This rare genetic disorder affects about one in every 100,000 to 200,000 newborns, and the new option gives patients their first real choice in managing it. Cystinosis leads to harmful crystal buildup in the body, starting in the kidneys and eyes before spreading to other organs. Families have long pushed for better treatments, and this approval comes after years of effort by patient groups and experts. Understanding Cystinosis and Its Challenges Cystinosis is a tough condition caused…
